-+ 0.00%
-+ 0.00%
-+ 0.00%

Alzamend Neuro Phase 1/2A AL001 lithium imaging data wins oral slot at ISMRM X-Nuclei MR workshop

PUBT·08/18/2026 12:03:34
Listen to the news
Alzamend Neuro Phase 1/2A AL001 lithium imaging data wins oral slot at ISMRM X-Nuclei MR workshop
  • Alzamend Neuro flagged Phase 1/2A brain-imaging results for AL001, its organic lithium candidate, slated for an ISMRM workshop oral talk.
  • Data will be presented September 29, 2026 in Barcelona, covering how AL001 distributes in brain tissue over time in healthy subjects.
  • Acceptance for an oral session signals external scientific vetting, supporting the program’s clinical positioning for better-tolerated lithium therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608180800PR_NEWS_USPR_____SF28561) on August 18, 2026, and is solely responsible for the information contained therein.